{"id":"W3195417065","doi":"10.1016/j.jaad.2021.06.569","title":"27374 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Adalimumab; Plaque psoriasis; Psoriasis; Monoclonal antibody; Dermatology; Interleukin 17; Monoclonal; Internal medicine; Immunology; Antibody; Tumor necrosis factor alpha; Inflammation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001291841,0.001020605,0.002395173,0.0002272363,0.0003992093,0.001329815,0.0005937874,0.001028641,0.003614222],"category_scores_gemma":[0.0009076098,0.0003776194,0.002067641,0.0003432763,0.0007585132,0.0008236506,0.0002704675,0.003409642,0.0008044971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006334314,"about_ca_system_score_gemma":0.0007076356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006453785,"about_ca_topic_score_gemma":0.00137272,"domain_scores_codex":[0.9995932,0.000160236,0.0000175396,0.00006786625,0.00004789326,0.0001133089],"domain_scores_gemma":[0.9995394,0.0001367916,0.00009042718,0.00003601682,0.00002662576,0.000170828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8428923,0.01028071,0.005134703,0.0009870313,0.002846793,0.0001585395,0.0001291618,0.001032644,0.01192182,0.0003132014,0.005916932,0.1183861],"study_design_scores_gemma":[0.8465909,0.1253656,0.02019381,0.00008732753,0.001589329,0.0002482812,0.00007036761,0.0009713193,0.001114499,0.0004478324,0.003279791,0.00004090926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866543,0.007762216,0.0003090998,0.0008090139,0.0003027093,0.0004816857,0.0006084861,0.0001197761,0.002952743],"genre_scores_gemma":[0.9915109,0.002704655,0.0005448001,0.001472759,0.0003396988,0.0004325658,0.001032761,0.00003340346,0.001928426],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003614222,"threshold_uncertainty_score":0.01209074,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02062054342886212,"score_gpt":0.2772263132695126,"score_spread":0.2566057698406505,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}